MIMETAS and Partners Launch World’s First Microphysiological Systems Industry Alliance

LEIDEN, the Netherlands, February 10, 2026 / Biotech Newswire / -- Today marks an important step for the global microphysiological systems (MPS) field with the launch of IAMPS – the Industry Alliance for Microphysiological Systems – the world’s first industry association dedicated to advancing MPS technologies. With MIMETAS as a founding member, IAMPS brings together nine pioneering companies – AlveoliX (Switzerland), BiomimX (Italy), chiron (Netherlands), Dynamic42 (Germany), InSphero (Switzerland), MIMETAS (Netherlands), NETRI (France), React4Life (Italy), and TissUse (Germany) – forming a strong coalition of innovators in organoids, organs-on-chips, and next generation human biology platforms. These technologies provide more predictive, ethical, and scalable alternatives to traditional animal and 2D models, accelerating drug development and supporting the global shift toward human-relevant science.
 
IAMPS will work proactively to advance regulatory acceptance, accelerate qualification and standardization, strengthen European biobanking and tissue access, and contribute to strategic EU investment. Together these activities support the scaling of the MPS field and broader adoption by regulators and industry.
 
The alliance is led by Thibault Honegger (NETRI), President of IAMPS, Paola Occhetta (BiomimX), VicePresident for Regulatory Adoption, and Jos Joore, CEO of MIMETAS and VicePresident for Legislation and Programmes at IAMPS.
 
Jos Joore commented: “Microphysiological systems are becoming essential to the future of drug development: humanrelevant, scalable, and transforming how therapies are discovered and evaluated. This technology was pioneered in Europe, and IAMPS provides a platform to help shape its global trajectory. By uniting leading innovators across the field, we can drive harmonized standards and deliver the scientific rigor needed to make MPS the worldwide norm for safe, fast, and effective drug development.”
 
Semantic keywords: Microphysiological Systems; Models, Animal; Biological Specimen Banks; Lab-On-A-Chip Devices; Organoids; Drug Discovery; Biotechnology; Netherlands; MIMETAS; Industry Alliance; Microphysiological Systems; IAMPS; MPS technologies; AlveoliX; BiomimX; chiron; Dynamic42; InSphero; NETRI; React4Life; TissUse; organs-on-chips; ethical alternatives; accelerating drug development; regulatory acceptance; European biobanking; tissue access; Thibault Honegger; Paola Occhetta; Jos Joore
 
About MIMETAS
MIMETAS is a global leader in disease modeling using advanced organ-on-a-chip technology. Through their OrganoPlate® platform, they offer screenable, physiologically relevant 3D human tissue models that accelerate drug discovery and reduce reliance on animal testing. Combining technical expertise and innovative modeling, MIMETAS collaborates with global pharmaceutical companies to accelerate the development of safe and effective therapies. In addition to custom drug discovery services, MIMETAS provides off-the-shelf products, supporting research worldwide. With operations across the United States, Europe, and Asia, MIMETAS is at the forefront of transformative biotech solutions.